about
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing programThe Host Cell Receptors for Measles Virus and Their Interaction with the Viral Hemagglutinin (H) ProteinTargeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virusLibrary-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells.A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy.Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.Current issues and future directions of oncolytic adenoviruses.Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinomaSeneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancersIn vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancerToll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors.Conditionally replicative adenovirus for gastrointestinal cancers.Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virus.Gene therapy trials for the treatment of high-grade gliomas.Oncolytic measles viruses for cancer therapy.Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients.Fighting cancer with oncolytic viruses.Progress in gene therapy for prostate cancerGene therapy of gynaecological diseases.Adenoviral virotherapy for malignant brain tumorsEngineering oncolytic measles virus to circumvent the intracellular innate immune response.Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer modelsNew perspectives in cancer virotherapy: bringing the immune system into play.Use of attenuated paramyxoviruses for cancer therapy.Oncolytic viruses: do they have a role in anti-cancer therapy?Oncolytic viruses in the treatment of cancer: a review of current strategies.Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function.Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme.Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and HostVesiculovirus neutralization by natural IgM and complement.Oncolytic adenoviruses: design, generation, and experimental procedures.Systems Biomedicine of Rabies Delineates the Affected Signaling Pathways.Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.Directed adenovirus evolution using engineered mutator viral polymerases.A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.
P2860
Q24627862-E45B61EB-08EA-460A-A86E-C9373BEFFCA1Q28069519-4DFED117-BE7A-47D1-A082-D66B3BA63256Q28755816-3834CF75-4F8B-4B8B-AEEA-1DB73F0CD029Q31148079-66765F6F-8488-4D5E-8127-E19694D4400CQ33299767-680417E7-DD97-4E00-9D44-780076C7EDDEQ33652517-5A939756-4546-4D44-B0A1-ADFACB02F8E8Q33691838-7EDC8794-A91F-4B12-AB68-CD3AE6A8D9EBQ33730705-AF0100FE-D929-4AE6-9CC0-BC944E453F63Q33731148-C7634899-F25B-460E-8968-8E137A28EC72Q34707959-E0B5488A-19E1-41A0-BF73-F062F3429B2CQ34997475-2F661549-22C2-434D-9572-34D0BA80C7F7Q35751039-F546BCC4-C797-460B-9EA5-1A81755B83BCQ35842604-7B28F659-92CE-4908-ACDD-CCBA9AD3739EQ35842621-A8082300-8089-4BA6-8D4D-A08C0729BACDQ35880459-3F7B4EEB-CCCE-4DF7-8636-CBE66F35419AQ35907056-467F1CD4-E518-40E1-AB30-B38F2387B7A1Q36007610-39C687E2-568C-4068-A7A9-E18B394FB8ABQ36099082-EDF36D90-E2C1-4519-8C28-5F06B9A088E5Q36373017-732536B3-5CE1-460A-958E-0A6F9ACB0650Q36406911-1EFFFDCE-26A2-4DA1-A3AD-C235D17E4852Q36922247-6D159765-733B-4A7A-9030-316D746E2EE4Q37223846-43CC9761-7ABF-42F9-A9F6-C48927202EAFQ37324179-2F042C41-03AA-4E08-8607-1A5D5375D48AQ37336713-80C240ED-1892-4942-B3A0-47CEDD72A15AQ37360204-F7612C63-06FE-48B2-B460-137C26764B2EQ37629550-E2138FFD-AED5-458A-AEFB-278CEC2C6139Q37773253-3045E837-6CFE-4C58-8ED4-A78A351317DFQ37810599-B80B0B7A-F2F4-4521-A13D-182E691D1255Q37926486-BDCA38C1-0A94-4D64-994A-E24FF98BBF7DQ38020107-24909BC4-C51A-4E0F-9E76-759E2918F403Q38161930-3C6999F2-8060-48B4-907A-EEBB9C45B2B2Q38253056-B2CF84A1-8372-435E-BC55-31DC4B3BD39FQ38369289-22FBA835-34BD-4BCB-9A6F-973CCE7DCDF5Q39013686-CD23ABD4-C80C-4112-A781-3F23A8079309Q39125899-14936BD1-923C-4D9F-9672-74003F891EB7Q39166204-022C9920-3FD9-4E17-A339-A8E1798C0F4FQ39473679-F2C30F5A-6EBF-49B6-93D6-13E79A86FF54Q39588655-4C67C297-C2D3-4ADD-BAEB-62596C4FE3F0Q39622784-87759C62-98D2-4543-BD3B-388599C6B878Q39709581-9CD67F12-DC54-408A-AC7E-1C708C092C4E
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
RNA viruses as virotherapy agents.
@en
type
label
RNA viruses as virotherapy agents.
@en
prefLabel
RNA viruses as virotherapy agents.
@en
P2860
P356
P1433
P1476
RNA viruses as virotherapy agents.
@en
P2093
Stephen J Russell
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700535
P577
2002-12-01T00:00:00Z